Trial · NCT05660967
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
NCT05660967, Phase 2, Terminated, Genmab
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma. Trials, record NCT05660967. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05660967
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
- NCT number
- NCT05660967
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 111 participants, actual
- Lead sponsor
- Genmab
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Epcoritamab, Lenalidomide
- First posted
- 2022-12-21
- Last updated
- 2026-10-23
- Other registries' IDs
- eudract:2021-005744-29
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete Response (CR) rate | From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years | Percentage of participants achieving CR. Assessed by the Investigator per Lugano criteria |
| Secondary | Duration of response (DOR) | From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years | Defined as the time between date of first response to the date of first documented tumor progression or death (due to any cause) whichever occurs first |
| Secondary | Duration of complete response (DOCR) | From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years | Defined as the time between the date of first CR to the date of the first documented tumor progression or death due to any cause, whichever comes first |
| Secondary | Time to response (TTR) | From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 1 year | Defined as the time from first dose to first documentation of objective tumor response (CR or PR) |
| Secondary | Overall Response Rate (ORR) | From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years | Defined as the percentage of patients who achieve best overall response of complete response (CR) or partial response (PR) determined by Lugano criteria |
| Secondary | Progression-free survival (PFS) | From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years | Defined as the time from first dose to date of PD or death (due to any cause) whichever occurs first |
| Secondary | Time to next anti-lymphoma therapy (TTNT) | From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years | Defined as the time from first dose to administration of subsequent anti-lymphoma therapy |
| Secondary | Rate of minimal residual disease (MRD) negativity | From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 2 years | Percentage of participants with at least 1 post-screening MRD negative result |
| Secondary | Overall survival (OS) | From randomization (for patients enrolled in stage 1) or from first dose (for patients enrolled in stage 2) and up to 3 years | Defined at the timeframe from first dose to death |
| Secondary | Incidence and severity of adverse events (AEs) | From screening until end of the safety follow-up period (60 days after last dose) | An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42285113 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05660967
GET https://conductscience.org/api/trials/v1/NCT05660967/registered